Nifty
:
22795.90
Sensex
:
75311.06
-117.25 (-0.51%)
-424.90 (-0.56%)
Nifty
Sensex
:
:
22795.90
75311.06
-117.25 (-0.51%)
-424.90 (-0.56%)

Alkem Laboratories Ltd.

Pharmaceuticals & Drugs - Domestic

Rating :
N/A

BSE: 539523 | NSE: ALKEM

NSE BSE
5255.70
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  5095.00
  •  5271.95
  •  5095.00
  •  5117.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  153921
  •  8052.51
  •  6439.90
  •  4407.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 55,067.45
  • 25.57
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 54,351.47
  • 0.87%
  • 4.54

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 55.66%
  • 0.13%
  • 15.90%
  • FII
  • DII
  • Others
  • 10.15%
  • 16.84%
  • 1.32%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.96
  • 8.71
  • 6.01

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.20
  • 8.79
  • 1.81

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.45
  • 9.76
  • 2.95

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.03
  • 28.58
  • 34.78

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.90
  • 5.04
  • 5.05

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.41
  • 20.45
  • 21.89

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
150.19
186.1
209.24
233.03
P/E Ratio
36.29
29.28
26.05
23.39
Revenue
12439
13324
14709
16134
EBITDA
2279
2595
2972
3432
Net Income
1796
2229
2513
2793
ROA
12.2
14.1
14.3
14.8
P/Bk Ratio
6.32
5.44
4.72
4.13
ROE
18.55
19.74
19.23
18.17
FCFF
1836.94
1741.09
1610.77
2100.8
FCFF Yield
2.8
2.65
2.45
3.2

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
3,374.28
3,323.87
1.52%
3,414.67
3,440.17
-0.74%
3,031.82
2,967.72
2.16%
2,935.82
2,902.60
1.14%
Expenses
2,614.89
2,616.28
-0.05%
2,661.84
2,693.44
-1.17%
2,423.18
2,578.53
-6.02%
2,533.84
2,549.35
-0.61%
EBITDA
759.39
707.59
7.32%
752.83
746.73
0.82%
608.64
389.19
56.39%
401.98
353.25
13.79%
EBIDTM
22.51%
21.29%
22.05%
21.71%
20.08%
13.11%
13.69%
12.17%
Other Income
92.99
93.64
-0.69%
134.48
63.19
112.82%
120.31
65.84
82.73%
88.17
68.67
28.40%
Interest
36.03
25.46
41.52%
28.14
30.32
-7.19%
29.11
29.77
-2.22%
26.86
28.96
-7.25%
Depreciation
85.28
69.56
22.60%
78.91
73.90
6.78%
80.48
72.41
11.14%
83.43
78.32
6.52%
PBT
731.07
654.90
11.63%
780.26
648.04
20.40%
619.36
352.85
75.53%
367.34
211.66
73.55%
Tax
90.28
50.62
78.35%
78.30
33.15
136.20%
69.12
65.04
6.27%
62.86
143.98
-56.34%
PAT
640.79
604.28
6.04%
701.96
614.89
14.16%
550.24
287.81
91.18%
304.48
67.68
349.88%
PATM
18.99%
18.18%
20.56%
17.87%
18.15%
9.70%
10.37%
2.33%
EPS
52.35
49.77
5.18%
57.60
51.90
10.98%
45.60
23.98
90.16%
24.56
5.94
313.47%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
12,756.59
12,667.58
11,599.26
10,634.19
8,865.01
8,344.36
7,357.19
6,391.84
5,687.53
4,924.84
3,743.35
Net Sales Growth
0.97%
9.21%
9.08%
19.96%
6.24%
13.42%
15.10%
12.38%
15.49%
31.56%
 
Cost Of Goods Sold
4,592.38
4,327.06
4,381.43
3,565.78
3,124.81
2,959.14
2,586.30
1,986.45
1,807.71
1,630.87
1,453.41
Gross Profit
8,164.21
8,340.52
7,217.83
7,068.41
5,740.20
5,385.22
4,770.89
4,405.39
3,879.82
3,293.97
2,289.94
GP Margin
64.00%
65.84%
62.23%
66.47%
64.75%
64.54%
64.85%
68.92%
68.22%
66.88%
61.17%
Total Expenditure
10,233.75
10,422.09
9,989.81
8,581.27
6,922.62
6,870.97
6,242.42
5,382.92
4,688.58
4,071.59
3,321.52
Power & Fuel Cost
-
162.58
163.94
162.96
129.95
130.14
121.48
112.64
86.34
66.33
53.31
% Of Sales
-
1.28%
1.41%
1.53%
1.47%
1.56%
1.65%
1.76%
1.52%
1.35%
1.42%
Employee Cost
-
2,201.01
2,131.35
1,962.71
1,621.03
1,505.49
1,362.46
1,191.64
1,003.85
861.08
645.87
% Of Sales
-
17.38%
18.37%
18.46%
18.29%
18.04%
18.52%
18.64%
17.65%
17.48%
17.25%
Manufacturing Exp.
-
1,183.76
972.37
1,092.63
748.03
765.43
806.17
838.87
692.26
550.16
367.58
% Of Sales
-
9.34%
8.38%
10.27%
8.44%
9.17%
10.96%
13.12%
12.17%
11.17%
9.82%
General & Admin Exp.
-
833.21
819.84
641.25
506.77
525.62
512.52
469.90
379.78
334.28
238.92
% Of Sales
-
6.58%
7.07%
6.03%
5.72%
6.30%
6.97%
7.35%
6.68%
6.79%
6.38%
Selling & Distn. Exp.
-
1,307.60
1,339.88
1,070.10
700.98
854.48
726.21
675.43
596.44
503.69
434.56
% Of Sales
-
10.32%
11.55%
10.06%
7.91%
10.24%
9.87%
10.57%
10.49%
10.23%
11.61%
Miscellaneous Exp.
-
406.87
181.00
85.84
91.05
130.67
127.28
107.99
122.20
125.18
434.56
% Of Sales
-
3.21%
1.56%
0.81%
1.03%
1.57%
1.73%
1.69%
2.15%
2.54%
3.42%
EBITDA
2,522.84
2,245.49
1,609.45
2,052.92
1,942.39
1,473.39
1,114.77
1,008.92
998.95
853.25
421.83
EBITDA Margin
19.78%
17.73%
13.88%
19.30%
21.91%
17.66%
15.15%
15.78%
17.56%
17.33%
11.27%
Other Income
435.95
310.84
216.08
162.65
233.21
104.22
87.70
115.42
112.01
239.71
181.04
Interest
120.14
112.41
107.36
52.37
58.92
65.06
54.63
55.33
45.16
71.24
81.11
Depreciation
328.10
299.30
310.42
303.96
274.58
252.76
193.18
143.03
101.17
93.31
70.94
PBT
2,498.03
2,144.62
1,407.75
1,859.24
1,842.10
1,259.79
954.66
925.98
964.63
928.41
450.82
Tax
300.56
211.67
297.96
163.96
224.33
110.48
181.02
287.56
59.96
176.18
59.23
Tax Rate
12.03%
10.46%
22.84%
8.89%
12.18%
8.77%
18.96%
31.05%
6.22%
18.98%
13.14%
PAT
2,197.47
1,795.77
984.17
1,645.62
1,585.02
1,127.07
760.51
630.94
892.03
741.59
391.59
PAT before Minority Interest
2,153.18
1,811.46
1,006.81
1,680.32
1,617.77
1,149.31
773.64
638.42
904.67
752.23
391.59
Minority Interest
-44.29
-15.69
-22.64
-34.70
-32.75
-22.24
-13.13
-7.48
-12.64
-10.64
0.00
PAT Margin
17.23%
14.18%
8.48%
15.47%
17.88%
13.51%
10.34%
9.87%
15.68%
15.06%
10.46%
PAT Growth
39.55%
82.47%
-40.19%
3.82%
40.63%
48.20%
20.54%
-29.27%
20.29%
89.38%
 
EPS
183.73
150.15
82.29
137.59
132.53
94.24
63.59
52.75
74.58
62.01
32.74

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
10,312.06
9,045.29
8,637.90
7,376.73
6,160.67
5,439.34
4,863.77
4,467.64
3,691.96
2,999.05
Share Capital
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
Total Reserves
10,268.61
9,020.78
8,613.39
7,351.70
6,135.40
5,413.93
4,838.87
4,443.34
3,668.03
2,975.14
Non-Current Liabilities
-648.88
-688.00
-892.74
-750.71
-540.58
-288.92
-358.61
-400.78
-306.15
200.60
Secured Loans
40.00
0.00
0.03
18.47
63.60
219.80
122.12
175.01
112.49
33.43
Unsecured Loans
0.00
0.00
9.35
9.46
10.31
11.50
8.61
6.55
10.97
0.00
Long Term Provisions
299.86
369.36
332.75
250.73
222.98
173.72
150.27
102.17
82.96
66.58
Current Liabilities
3,994.55
3,707.15
4,805.34
3,604.05
3,244.58
2,217.53
2,383.31
1,689.69
1,537.60
2,005.98
Trade Payables
1,748.12
1,165.03
1,173.38
1,069.41
954.05
962.25
960.71
741.37
580.48
465.93
Other Current Liabilities
891.94
838.81
771.42
643.11
555.47
428.08
520.04
339.25
366.01
327.06
Short Term Borrowings
1,172.63
1,307.12
2,570.62
1,635.96
1,503.51
671.27
761.27
472.37
464.17
1,128.57
Short Term Provisions
181.86
396.19
289.92
255.57
231.55
155.93
141.29
136.70
126.94
84.42
Total Liabilities
14,060.07
12,454.15
12,759.93
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43
5,291.28
Net Block
2,872.78
2,682.85
2,901.73
2,792.98
2,908.01
2,530.44
2,283.59
1,797.04
1,449.54
1,374.34
Gross Block
4,543.70
4,050.24
4,185.64
3,768.89
3,606.95
3,026.08
2,603.78
1,977.20
1,538.64
1,744.89
Accumulated Depreciation
1,629.36
1,367.39
1,283.91
975.91
698.94
495.64
320.19
180.16
89.10
370.55
Non Current Assets
3,648.49
3,724.47
4,324.50
3,482.53
3,507.32
3,284.43
2,996.80
2,954.64
2,249.73
2,953.23
Capital Work in Progress
158.57
323.24
339.48
393.28
362.97
492.96
380.97
299.26
172.42
110.69
Non Current Investment
334.80
304.61
231.67
153.95
91.50
95.74
98.45
259.44
234.39
419.73
Long Term Loans & Adv.
203.74
139.07
154.44
93.77
98.16
118.64
141.37
193.07
142.35
542.17
Other Non Current Assets
78.60
274.70
697.18
48.55
46.68
46.65
92.42
405.83
251.03
506.30
Current Assets
10,411.58
8,606.42
8,433.70
6,928.82
5,505.65
4,216.13
4,013.22
2,917.14
2,768.70
2,338.05
Current Investments
148.99
317.21
139.31
178.83
169.89
227.88
345.82
293.56
274.18
61.05
Inventories
2,661.18
2,607.53
3,005.53
2,312.44
1,818.82
1,499.87
1,442.19
1,206.00
909.37
784.23
Sundry Debtors
2,252.81
2,132.18
1,884.60
1,607.21
1,649.36
1,248.41
1,080.50
713.64
567.51
527.08
Cash & Bank
1,579.35
2,616.89
2,578.58
1,990.45
1,092.21
661.60
576.78
399.26
780.90
790.76
Other Current Assets
3,769.25
244.68
239.80
335.19
775.37
578.37
567.93
304.68
236.74
174.93
Short Term Loans & Adv.
3,532.12
687.93
585.88
504.70
482.24
405.00
390.63
171.35
141.30
114.85
Net Current Assets
6,417.03
4,899.27
3,628.36
3,324.77
2,261.07
1,998.60
1,629.91
1,227.45
1,231.10
332.07
Total Assets
14,060.07
12,330.89
12,758.20
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43
5,291.28

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
1,948.07
1,682.50
1,111.02
1,264.90
585.08
779.65
266.04
471.14
725.83
325.47
PBT
2,023.13
1,304.77
1,844.28
1,842.10
1,259.79
954.66
925.98
964.63
928.41
450.82
Adjustment
383.57
324.35
208.60
164.64
255.87
216.37
116.47
33.02
-14.42
-7.82
Changes in Working Capital
-51.69
326.77
-544.96
-341.16
-647.20
-140.27
-573.24
-262.55
10.05
-11.89
Cash after chg. in Working capital
2,355.01
1,955.89
1,507.92
1,665.58
868.46
1,030.76
469.21
735.10
924.04
431.11
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-406.94
-273.39
-396.90
-400.68
-283.38
-251.11
-203.17
-263.96
-198.21
-105.64
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,008.50
112.84
-1,435.13
-998.54
-741.35
-316.39
-357.23
-285.93
202.27
-236.97
Net Fixed Assets
-74.10
-101.58
-254.26
-139.76
-310.63
-342.15
-531.27
-390.07
160.79
-111.90
Net Investments
176.57
-476.94
-376.23
-196.34
-260.44
-151.10
-26.86
-359.97
-87.11
-129.77
Others
-1,110.97
691.36
-804.64
-662.44
-170.28
176.86
200.90
464.11
128.59
4.70
Cash from Financing Activity
-1,145.01
-1,760.82
379.57
-271.75
79.15
-378.94
84.56
-137.88
-927.27
-51.78
Net Cash Inflow / Outflow
-205.44
34.52
55.46
-5.39
-77.12
84.32
-6.63
47.33
0.83
36.72
Opening Cash & Equivalents
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.03
123.75
100.82
Closing Cash & Equivalent
66.31
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.05
139.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
860.94
756.56
722.48
616.95
515.21
454.86
406.76
373.67
308.82
250.86
ROA
13.66%
7.99%
14.50%
16.66%
13.92%
10.66%
9.91%
16.61%
14.59%
8.16%
ROE
18.74%
11.39%
20.99%
23.91%
19.82%
15.02%
13.69%
22.18%
22.47%
14.03%
ROCE
19.52%
13.09%
18.69%
22.56%
18.71%
16.49%
17.86%
21.31%
23.09%
13.27%
Fixed Asset Turnover
4.51
4.36
3.84
3.56
3.74
3.80
3.75
3.33
3.07
2.65
Receivable days
41.28
40.86
41.72
45.33
42.66
39.69
38.15
39.95
39.57
42.27
Inventory Days
49.60
57.10
63.54
57.51
48.86
50.14
56.31
65.96
61.23
66.41
Payable days
122.87
97.40
114.79
118.18
52.05
60.17
61.04
52.36
49.96
45.83
Cash Conversion Cycle
-31.98
0.57
-9.53
-15.34
39.47
29.66
33.42
53.55
50.84
62.85
Total Debt/Equity
0.12
0.14
0.30
0.23
0.26
0.17
0.21
0.15
0.18
0.44
Interest Cover
19.00
13.15
36.22
32.26
20.36
18.48
17.74
22.36
14.03
6.56

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Alkem Laboratories reports 6% rise in Q3 consolidated net profit
    7th Feb 2025, 15:29 PM

    Total consolidated income of the company increased by 1.46% at Rs 3467.27 crore for Q3FY25

    Read More
  • Alkem Laboratories - Quarterly Results
    7th Feb 2025, 13:49 PM

    Read More
  • Alkem Laboratories to sell Pithampur manufacturing facility to Rubicon Research
    7th Jan 2025, 14:26 PM

    The sale is part of an ongoing initiative of networking strategy and optimisation of manufacturing facilities

    Read More
  • Alkem Laboratories to make equity investment in Sunsure Solarpark
    18th Dec 2024, 11:43 AM

    The said investment will be completed by the end of April, 2025

    Read More
  • Alkem Laboratories gets nod to transfer trade generics business to M/s. Alkem Wellness
    10th Dec 2024, 14:27 PM

    The Board of Directors of Alkem Laboratories at its meeting held on December 10, 2024 has approved the same

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.